Sirolimus long term side effects: what the data shows

Last updated 2026-07-27

What does "long term" even mean for sirolimus right now?

Right now, "long term" for sirolimus mostly means transplant data, not longevity data. The FDA approved sirolimus (brand name Rapamune) in 1999 for kidney transplant rejection, and that approval rests on trials where patients took it continuously, every day, for years, usually alongside other immunosuppressants ^[1]. That is where almost all of the multi-year human safety data comes from. The use case longevity researchers care about, low doses taken once or twice weekly to try to slow aging, has no equivalent long-term dataset. No randomized controlled trial has followed healthy humans taking intermittent low-dose rapamycin for five years, ten years, or longer, and measured mortality or chronic disease outcomes. The PEARL trial, run out of AKG Life Sciences and university partners, is one of the few structured attempts to study this in healthy older adults, but it is short in duration and not designed to answer lifetime safety questions ^[2]. So when someone asks "what are the long-term side effects of sirolimus," the honest answer splits in two: what we know from decades of transplant use at higher doses, and what we don't know at all about low-dose intermittent use in otherwise healthy people. Conflating the two is the single biggest source of bad information in this space. For readers making a decision, that gap matters more than any individual side effect. See Sirolimus Rx results: what the research shows for how the human evidence stacks up against the animal data.

What is the long-term human safety data actually based on?

The long-term human safety data on sirolimus comes almost entirely from solid organ transplant recipients, a population that is older, sicker, and on multiple other drugs, not from healthy adults taking it for longevity. That distinction matters for interpreting every number below. Rapamune's FDA label, based on trials in kidney transplant patients, lists common adverse reactions including hyperlipidemia, hypertension, peripheral edema, thrombocytopenia, anemia, and increased risk of infection, observed in patients taking sirolimus continuously in combination with cyclosporine and corticosteroids ^[1]. These are not intermittent, low-dose patients. They're transplant patients on doses several times higher than what longevity protocols typically use, often 2-5 mg per day versus roughly 5-10 mg once weekly in off-label longevity dosing. A large registry analysis and multiple long-term transplant studies have also linked sirolimus-based regimens to worse wound healing and lymphocele formation, and some analyses found higher early mortality in de novo kidney transplant use compared to calcineurin inhibitor-based regimens, though these findings are specific to the transplant, continuous-dosing context ^[3]. None of this tells you what happens to a healthy 50-year-old taking 6mg once a week for a decade. Nobody has that data yet. The mouse data, by contrast, is genuinely strong and comes from a well-controlled source: the National Institute on Aging's Interventions Testing Program (ITP), which has repeatedly found that rapamycin extends median and maximum lifespan in genetically heterogeneous mice, even when started late in life, with effects seen across multiple independent labs ^[4]. That's the strongest lifespan-extension signal in the mammalian aging field. But mice are not humans. The ITP doses and schedules don't map cleanly onto human intermittent protocols.

Does long-term sirolimus use cause immunosuppression?

Yes. Immunosuppression is the core, expected, mechanistically obvious effect of sirolimus, and it does not disappear just because the dose is low or intermittent. Sirolimus is an mTOR inhibitor, and mTOR signaling is central to T cell activation and immune proliferation, which is exactly why the drug works to prevent transplant rejection ^[1]. In continuous transplant dosing, this shows up as a documented increased risk of infection, including opportunistic infections, and the FDA label carries specific warnings about this ^[1]. In lower, intermittent longevity dosing, the working theory (and it is a theory, not a proven fact) is that once-weekly dosing lets immune function partially recover between doses, unlike the sustained suppression of daily transplant dosing. A small study in older adults found that low, intermittent doses of an mTOR inhibitor improved flu vaccine response and appeared to reduce infection rates over the following year, relative to placebo ^[5]. But "partially recovers over days" is not the same claim as "stays safe over years." Nobody has run a multi-year trial tracking infection rates, wound healing, or vaccine response in healthy adults on intermittent low-dose sirolimus. If you are on it long-term, routine bloodwork and honest tracking of infections and healing time is not optional. See Sirolimus Rx and blood work for what to monitor and how often.

Are mouth ulcers a long-term problem or do they go away?

Mouth ulcers (stomatitis) are one of the most consistently reported side effects of sirolimus, and for many people they are worst in the first weeks to months, then improve, though they can recur, especially after a dose increase. In transplant trials, stomatitis and mouth ulcers were among the more common adverse events reported with sirolimus ^[1]. In practice, people running intermittent longevity protocols report that ulcers are dose-dependent and often improve as the body adjusts, sometimes resolving with a modest dose reduction. This pattern (early, dose-related, sometimes fading) is a real observation from clinical and anecdotal reports, not a formal long-term study of intermittent dosing in healthy adults. Whether ulcers reliably stay quiet over years of continued use, or return periodically, is not something any trial has tracked systematically. Practical management people use: rinsing with plain water after the dose, avoiding acidic or spicy food on dosing days, and using a bland barrier gel. If ulcers are severe or don't improve, that's a signal for a prescriber to review the dose, not something to push through silently.

What are the long-term metabolic side effects of sirolimus?

The metabolic profile is genuinely mixed. It's one of the more interesting tensions in the whole rapamycin story: the drug that extends lifespan in mice also nudges human lipid and glucose numbers in the wrong direction in some studies. Elevated cholesterol and triglycerides (hyperlipidemia) are listed as common adverse reactions in the Rapamune label, based on transplant patients on continuous dosing ^[1]. On glucose, the picture is more nuanced. Some rodent and short-term human studies have raised concern about mTOR inhibition worsening insulin sensitivity, particularly with continuous high-dose exposure, while other intermittent-dosing studies in humans have not shown the same effect, and a few have shown neutral or even mildly favorable immune and metabolic markers over a period of months ^[2][5]. The honest summary: continuous high-dose sirolimus in transplant patients has a real signal for worsened lipids and, in some contexts, glucose handling. Intermittent low-dose use in healthy people looks better on short-term markers, but "short-term" is the key word. No one has lipid and HbA1c data on the same cohort of low-dose users at year one, five, and ten. If you're on sirolimus long-term, a fasting lipid panel and HbA1c or fasting glucose at baseline and at regular intervals is the minimum reasonable monitoring, not a nice-to-have.

Does sirolimus affect wound healing and surgery risk long term?

Yes, and this is one of the better-established long-term risks. Impaired wound healing is a recognized effect of sirolimus, tied directly to its mechanism. mTOR inhibition slows the cell proliferation and protein synthesis that wound repair depends on. The FDA label specifically warns about impaired or delayed wound healing, including increased risk of surgical wound complications, lymphocele, and fascial dehiscence, based on transplant surgery data ^[1]. The practical takeaway for anyone on a long-term protocol: if you have elective surgery, dental extractions, or any planned procedure with a wound-healing component, this needs to be discussed with the treating clinician, and most protocols call for pausing sirolimus for a defined window before and after surgery. This is not a theoretical risk category. It is one of the clearest, most mechanistically direct long-term risks the drug carries, and it applies regardless of whether the dosing is daily transplant-style or weekly longevity-style, because the biology does not distinguish between the two.

What does the animal lifespan data actually show, and why doesn't it prove humans benefit?

The animal data is the strongest part of the rapamycin longevity story, and it deserves to be stated plainly and without hedging on the mouse side, then hedged hard on the human extrapolation. The NIA's Interventions Testing Program, running since 2004 across three research sites (Jackson Laboratory, University of Michigan, University of Texas Health Science Center at San Antonio), found that rapamycin extended median lifespan in genetically heterogeneous mice, with effects replicated across cohorts and shown even when treatment started as late as 600 days of age (roughly equivalent to late middle age in mice) ^[4]. This is widely regarded as one of the more reliable findings in the aging-intervention field, because it was replicated across independent sites using a pre-registered, blinded protocol, which is rare in this field. But extrapolating mouse lifespan data to human aging carries real limits. Mice have short lifespans, different baseline mTOR activity, and live in controlled lab conditions without the comorbidities, medications, and genetic diversity of aging humans. Multiple longevity researchers and NIA program materials have noted that dose, schedule, and duration in mice do not map directly onto safe or effective protocols in humans. No completed randomized controlled trial has measured whether sirolimus extends human lifespan or reduces all-cause mortality. That gap is the whole story, and any article or influencer who elides it is not being straight with you. For a fuller breakdown of the animal-to-human evidence gap, see Sirolimus Rx before and after claims, which looks specifically at what anecdotal "before and after" reports can and can't tell you.

Who should not take sirolimus long term?

Some groups have long-term risk profiles that are clear enough to state directly, and these overlap heavily with standard contraindications rather than being unique to longevity dosing. People with active infections, a history of poor wound healing, uncontrolled hyperlipidemia, significant kidney impairment, or a planned pregnancy should not be starting a long-term sirolimus protocol without a prescriber weighing these specifically. The FDA label carries a boxed warning context around increased susceptibility to infection and the potential for lymphoma with immunosuppressive use, primarily documented in transplant populations on combination immunosuppression ^[1]. Whether that risk profile applies at low intermittent longevity doses is unknown, but the mechanism (immune suppression) is not different in kind, only in degree. Anyone with a personal or strong family history of skin cancer also warrants caution and closer monitoring, since immunosuppression broadly is associated with increased skin cancer risk in transplant literature, again primarily documented at higher continuous doses ^[3]. This is a case where absence of long-term low-dose data should push toward more caution, not less. For the full list of who this drug is not right for, see Sirolimus Rx contraindications.

How is long-term sirolimus use monitored?

Long-term monitoring for sirolimus, even at low intermittent doses, generally includes periodic blood levels, a lipid panel, kidney function tests, complete blood count, and glucose or HbA1c, though there's no single universally agreed protocol for longevity-focused low-dose use the way there is for transplant dosing. In transplant medicine, sirolimus trough blood levels are routinely measured because the therapeutic window is narrow and levels vary by individual metabolism, weight, and interacting medications ^[1]. In longevity protocols, some prescribers use blood level testing to individualize dosing, since studies have shown wide inter-individual variation in how people metabolize the drug, meaning the same milligram dose can produce very different blood levels between two people. This is one of the more practical, actionable pieces of long-term risk management available right now, even without long-term trial data. At minimum, a reasonable long-term monitoring cadence includes lipid panel and metabolic panel every 3-6 months, complete blood count periodically, and a conversation about any planned surgery or dental work well in advance. See Sirolimus Rx and blood work for the specific panels and intervals typically used, and Sirolimus Rx dosage calculator for how weight-based and blood-level-informed dosing is typically approached.

Is sirolimus the same thing as rapamycin, and does that matter for long-term risk?

Yes, sirolimus and rapamycin are the same molecule. Rapamycin was the original name given to the compound after its discovery in soil bacteria on Easter Island (Rapa Nui) in the 1970s, and sirolimus is the generic drug name used once it was developed pharmaceutically ^[1]. Everolimus is a related but chemically distinct mTOR inhibitor (a rapamycin analog, sometimes called a "rapalog"), with its own separate approval history and side effect profile, and should not be assumed to carry an identical long-term risk profile. This naming overlap matters for long-term safety research specifically because some studies, headlines, and supplement marketing use "rapamycin" and "sirolimus" interchangeably, but not every mTOR inhibitor study (some use everolimus, some use rapalogs) applies directly to sirolimus. When evaluating a long-term safety claim, check whether the underlying study actually used sirolimus/rapamycin or a related but different rapalog. This distinction gets lost constantly in longevity media and it changes what a given study can honestly tell you.

What does off-label, unregulated sourcing add to long-term risk?

Because sirolimus for longevity is entirely off-label, it is prescribed and dispensed outside the FDA-approved transplant indication, and that shifts responsibility for quality, dosing, and monitoring onto the prescriber, the pharmacy, and the patient rather than a manufacturer-run clinical protocol. The FDA has approved sirolimus (Rapamune) for kidney transplant rejection prophylaxis, and separately approved related formulations, Fyarro for certain soft tissue sarcomas and Hyftor as a topical for tuberous sclerosis-related skin lesions, but none of these approvals cover aging or lifespan extension ^[1]. That means anyone taking it long-term for longevity is, by definition, in off-label territory, and the quality and consistency of what's actually dispensed matters more, not less, given the total absence of long-term human trial safety data to fall back on. Sourcing from a legitimate, licensed pharmacy with actual testing and a physician reviewing labs is a meaningfully different long-term risk profile than sourcing from an unregulated online seller. Sirolimus Rx connects patients with providers who review labs and prescribe through a licensed U.S. pharmacy partner, rather than compounding or manufacturing anything itself, which is one practical way to reduce the sourcing-related slice of long-term risk, even though it does nothing to close the human-trial data gap. See Sirolimus Rx purity and testing for what to actually check before buying.

What would it take to actually know the long-term risks?

A completed, adequately powered, multi-year randomized controlled trial in healthy humans, tracking mortality, cancer incidence, infection rates, and metabolic markers against a placebo group, is what it would take, and nothing currently running meets that bar. The PEARL trial and similar smaller studies are steps in that direction, but they are short relative to a human lifespan and not designed as definitive mortality trials ^[2]. Until that kind of trial exists and reports results, anyone taking sirolimus long-term for longevity is participating in an informal, unmonitored experiment, and should treat it that way: with real bloodwork, a real prescriber relationship, and honest tracking of side effects rather than assuming the mouse data or short-term human studies settle the question. That is not a reason to dismiss the drug outright, given how strong the mouse data is. But it is a reason to be precise about what is proven and what is hoped for.

Frequently asked questions

What are the most common long-term side effects of sirolimus?

The best-documented long-term effects, based on transplant patients on continuous dosing, are mouth ulcers, elevated cholesterol and triglycerides, increased infection risk, impaired wound healing, and low platelet or red blood cell counts, per the FDA Rapamune label ^[1]. Whether these same risks apply at the same rate with low-dose intermittent longevity dosing has not been studied long-term.

Does sirolimus cause cancer with long-term use?

Immunosuppressive drugs as a class, including sirolimus in transplant regimens, carry increased risk of certain cancers, notably skin cancer and lymphoma, documented mainly in transplant patients on combination immunosuppression ^[1][3]. There is no long-term cancer incidence data specific to low-dose intermittent longevity use in healthy adults, so this risk cannot currently be ruled in or out at that dose.

Can long-term sirolimus use damage the kidneys?

In transplant patients, sirolimus has been associated with proteinuria and, in some regimens, kidney function changes, which is part of why trough blood levels and kidney function tests are routinely monitored in that population ^[1]. Kidney function monitoring is standard practice for long-term users, and pre-existing kidney impairment is a reason for extra caution or avoidance.

Is it safe to take sirolimus for 10 or 20 years?

Nobody knows yet. No completed clinical trial has followed healthy adults taking low-dose intermittent sirolimus for 10 or 20 years and measured outcomes. The longest continuous human safety data comes from transplant patients on different, higher, continuous dosing schedules, which doesn't directly answer the question for longevity-style use.

Do mouth ulcers from sirolimus get worse over time?

For most people, mouth ulcers tend to be worst early in treatment or after a dose increase, then improve, though they can recur. This pattern comes from clinical experience and transplant trial reporting rather than a dedicated long-term study of intermittent low-dose users, so persistence over many years hasn't been formally tracked.

Does low-dose intermittent dosing reduce long-term risk compared to daily dosing?

That is the working theory behind intermittent longevity protocols, based on the idea that immune function partially recovers between weekly doses, and one short-term study found improved vaccine response with intermittent mTOR inhibitor dosing. But no long-term trial has directly compared multi-year outcomes between intermittent and daily dosing in the same population ^[5].

Is rapamycin the same drug as sirolimus?

Yes. Rapamycin is the original compound name; sirolimus is the generic pharmaceutical name for the same molecule, marketed as Rapamune. Everolimus is a related but chemically distinct rapamycin analog with its own separate safety data, so studies on everolimus don't automatically apply to sirolimus.

What blood tests should someone on long-term sirolimus get?

A reasonable minimum includes a fasting lipid panel, complete blood count, kidney function tests, and glucose or HbA1c, checked periodically (commonly every 3 to 6 months), along with sirolimus blood trough levels to guide dosing given wide individual variation in drug metabolism. See a prescriber for a schedule tailored to your dose and history.

Does sirolimus actually extend human lifespan?

Nobody knows yet; this hasn't been tested in a completed human trial. Rapamycin reliably extends lifespan in mice in NIA Interventions Testing Program studies, even when started late in life ^[4], but no randomized controlled trial has measured whether sirolimus extends human lifespan or reduces mortality.

Can you have surgery or dental work while on long-term sirolimus?

You can, but it needs planning. Sirolimus impairs wound healing, and the FDA label specifically warns about surgical wound complications in transplant patients ^[1]. Most protocols involve pausing the drug for a defined window before and after any surgery or significant dental procedure; this should be discussed with the prescribing clinician in advance, not decided alone.

Who should avoid long-term sirolimus use entirely?

People with active infections, poor wound healing history, uncontrolled high cholesterol, significant kidney impairment, a personal or strong family history of certain cancers, or those planning pregnancy generally should not use it without a prescriber weighing the specific risk. These overlap with standard drug contraindications rather than being longevity-specific.

Is sirolimus FDA-approved for anti-aging use?

No. Sirolimus (Rapamune) is FDA-approved only for kidney transplant rejection prophylaxis; related formulations Fyarro and Hyftor are approved for specific cancers and a tuberous sclerosis skin condition ^[1]. Any use for aging, longevity, or lifespan extension is entirely off-label and not FDA-evaluated for that purpose.

Sources

1. FDA, Rapamune (sirolimus) Prescribing Information: FDA approval basis, common adverse reactions, wound healing and infection warnings for sirolimus
2. ClinicalTrials.gov, PEARL Trial (Participatory Evaluation of Aging with Rapamycin for Longevity): Ongoing/short-duration structured human study of low-dose intermittent rapamycin in healthy older adults
3. Knoll GA et al., "Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data," BMJ 2014;349:g6679: Long-term transplant registry findings on sirolimus, wound healing complications, and mortality risk in de novo use
4. Harrison DE et al., "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice," Nature 2009;460(7253):392-395: Rapamycin extends median and maximum lifespan in genetically heterogeneous mice across independent test sites, including when started late in life
5. Mannick JB et al., "mTOR inhibition improves immune function in the elderly," Science Translational Medicine 2014;6(268):268ra179: Short-term study on intermittent, low-dose mTOR inhibitor dosing and immune markers (vaccine response) in older adults